<DOC>
	<DOCNO>NCT00554619</DOCNO>
	<brief_summary>The primary objective study evaluate safety long-term administration GSK1325760A patient PAH . The secondary objective study evaluate long-term administration GSK1325760A : - Improvement exercise capacity ( six-minutes walk distance : 6MWD ) , change WHO Functional Classification time clinical worsen PAH - Change Borg Dyspnea Index ( assess immediately follow six-minute walk test [ 6MWT ] ) - Change plasma brain natriuretic peptide ( BNP ) level - Cardiopulmonary hemodynamics parameter ( measure echocardiography )</brief_summary>
	<brief_title>A Study Evaluate GSK1325760A - Long-Term Extension Study</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<criteria>Subjects complete 24week administration Phase II/III study ( Study No.AMB107816 ) Subjects assessed longterm extension administration GSK1325760A appropriate judgement investigator subinvestigator Subjects request longterm extension administration GSK1325760A , agree newly sign informed consent form Subjects withdrawn Phase II/III study . Female subject wish become pregnant . Treatment PAH medication need . A worsen 2 level WHO Functional Classification ( see Appendix 2.1 ) compare baseline Phase II/III study ( Study No.AMB107816 ) . Worsening right ventricular failure ( e.g . indicate increase jugular venous pressure , new/worsened hepatomegaly , ascites , peripheral edema ) Phase II/III study ( Study No.AMB107816 ) . Rapidly progress cardiac , hepatic renal failure Phase II/III study ( Study No.AMB107816 ) . Participation longterm extension study consider inappropriate judgment investigator subinvestigator .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Pulmonary Arterial Hypertension</keyword>
	<keyword>Ambrisentan</keyword>
</DOC>